Quick Answer
Allogene Therapeutics, Inc. reported Common Stock Shares Outstanding of 229.41 million shares for the year ending 2025.
- Allogene Therapeutics, Inc. showed an increase of +8.1% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from Allogene Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2017 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2017 to 2025), Allogene Therapeutics, Inc.'s Common Stock Shares Outstanding has grown by 774.0%.
- Historical annual values: Fiscal year 2025: 229.41 million shares | Fiscal year 2024: 212.21 million shares | Fiscal year 2023: 168.64 million shares | Fiscal year 2023: 168.18 million shares | Fiscal year 2023: 167.13 million shares | Fiscal year 2023: 145.74 million shares | Fiscal year 2022: 144.44 million shares | Fiscal year 2022: 144.03 million shares | Fiscal year 2022: 143.72 million shares | Fiscal year 2022: 143.57 million shares | Fiscal year 2021: 142.62 million shares | Fiscal year 2020: 140.47 million shares | Fiscal year 2019: 124.27 million shares | Fiscal year 2018: 121.48 million shares | Fiscal year 2017: 26.25 million shares.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: